Edwards Lifesciences Corp. remains on track to meet its one-year goal for training new centers to perform transcatheter aortic valve replacements with its Sapien device, but the recently established national Medicare coverage policy is inhibiting the effort to at least a small extent, the company suggests.
“Overall, we probably could have trained a few more sites than we did,” noted Michael Mussallem, CEO of Edwards, on the firm’s July 24 second-quarter earnings call